Condition 1: Fibromyalgia. Condition 2: Idiopathic peripheral autonomic neuropathy. Fibromyalgia Idiopathic peripheral autonomic neuropathy
Conditions
Interventions
Intervention 1: Control group (group A): The control group would be on the treatment with the standard medication of fibromyalgia (based on the latest available guidelines) including either Norepineph
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: American College of Rheumatology criteria for Fibromyalgia diagnosis Not using any medication for fibromyalgia and metformin
Exclusion criteria
Exclusion criteria: Comorbid disorders including history of cerebrovascular disease, rheumatoid arthritis, untreated endocrine abnormalities(except diabetes), autoimmune conditions, neuromuscular diseases, active malignancy, immuno-deficiency, advanced renal failure Taking medications associated with insulin resistance such as glucocorticoids, thiazide diuretics, atypical anti-psychotics,beta-blockers, niacin, statins and NSAID Drug or alcohol abuse Opium addiction or cigarette smoking Using any medication for fibromyalgia and metformin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain severity. Timepoint: At the first visit and 3 month after the beginning of interventions. Method of measurement: Numeric Pain Rating Scale (NPRS).;Fibromyalgia severity. Timepoint: At the first visit and 3 month after the beginning of interventions. Method of measurement: Revised Fibromyalgia Impact Questionnaire (FIQR).;Tender points. Timepoint: At the first visit and 3 month after the beginning of interventions. Method of measurement: Counting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropathy severity. Timepoint: At the first visit and 3 month after the beginning of interventions. Method of measurement: Toronto Clinical Neuropathy Scoring System (TCNS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Hallaji
Islamic Azad University
Outcome results
None listed